Navigation path

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece


   Infocentre

Published: 18 February 2016  
Related category(ies):
Health & life sciences  |  Human resources & mobility  |  Research policy

 

Countries involved in the project described in the article:
Germany
Add to PDF "basket"

Small molecule with a potentially big impact on Alzheimer's

Despite decades of research, a cure for Alzheimer's remains elusive. But work conducted in Europe suggests that the onset and progression of the disease could be prevented or slowed down by a molecule that mimics the activity of a critical protein (neurotrophin) affecting neurons in the brain.

Old man looks at the vintage picture of the girl

© bilderstoeckchen - Fotolia.com

Alzheimer’s current affects around 30 million people worldwide, and the figure is expected to rise as the population ages. The research, conducted in the EU-funded StressAmyloidCascade project, has demonstrated that drugs administered through the blood stream before the onset of Alzheimer-like symptoms in mice, can prevent age-associated cognitive impairments. The same treatment, based on a small-molecule synthetic compound called 7,8-DHF, also shows promise in slowing or even reversing cognitive decline after Alzheimer’s symptoms start to appear.

“Most current approaches to treating Alzheimer’s address the late stages of the disease when the pathology is hard to reverse and significant damage to mental health has already occurred. We therefore sought to identify windows during which therapeutic strategies to prevent or delay the onset of the disease would work,” explains Raul Delgado Morales, a Marie Curie fellow who conducted the research at the Max Planck Society for the Advancement of Science in Germany.

The StressAmyloidCascade team carried out the research using young adult mice genetically engineered to over-produce amyloid-beta (Abeta peptide), a compound that is strongly implicated in Alzheimer’s pathology.

Preventing and delaying cognitive impairment

While untreated mice showed obvious cognitive decline after five months, those treated with 7,8-DHF showed no impairments in spatial memory and had reduced levels of the neuron-endangering peptide Abeta in the hippocampus and frontal cortex – two brain areas involved in memory. In addition, when administration of 7,8-DHF began while the mice were middle-aged and Alzheimer’s symptoms had started to appear, the treatment slowed the cognitive decline.

“We already know of many potential drug targets, but drug development is hampered by not knowing how to target [them] effectively. 7,8-DHF is a small molecule that can easily enter the brain, does not have known side effects and is relatively cheap,” explains Osborne Almeida, the project coordinator. “Obviously, using mice to study a complex human disease has many limitations, but such studies are needed to demonstrate efficacy and examine pharmacology and toxicity, only then would limited human trials be ethically justified. At present, we have only studied a prototype drug: many more tests will be required, and further developments will depend on chemists who can design molecules with similar or better properties.”

The project team are seeking funding to continue their work and expand collaboration with scientists in other disciplines, focusing most immediately on identifying the exact mechanisms through which 7,8-DHF achieves its effects.

Though much more research is required, the achievements so far of StressAmyloidCascade nonetheless constitute an important contribution to Alzheimer’s research and could guide the development of new preventive treatments in the future, helping to lower the incidence of a disease that currently affects around 30 million people worldwide.

As the world’s population ages, that figure is expected to rise to more than 60 million by 2030 and 115 million by 2050, resulting in hundreds of billions of euros in costs for healthcare systems and an incalculable human cost in terms of the individual suffering of patients and their families.

“Our work represents a small, but committed [contribution] towards global efforts to fight Alzheimer’s,” the project coordinator says. “It places emphasis on the need for strategies that will prevent, delay or slow down disease onset and progression, improving quality of life for people who would otherwise become Alzheimer’s victims.”

Project details

  • Project acronym: STRESSAMYLOIDCASCADE
  • Participants: Germany (Coordinator)
  • FP7 Proj. N° 273720
  • Total costs: € 169 863
  • EU contribution: € 169 863
  • Duration: October 2012 - September 2014

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project information on CORDIS






  Top   Research Information Center
 
Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Finland
  France
  Gambia
  Georgia
  Germany
  Ghana
  Greece